Preclinical Oncology

When your research has the potential to save lives, you deserve a partner with the oncology pharmacology knowledge, breadth of tools and experience to move life-changing drug candidates through non-GLP, preclinical development andoncology clinical trialsquickly and efficiently.

We've helped hundreds of companies discover their next life-improving compound.

Browse hundreds ofcell line growth curves in our complete cell line listor read ourspotlights on tumor models.

We offer over 30 differentsyngeneic tumor models, from both solid and disseminated origins, to provide you with many choices to further your immuno-oncology research. We are continually improving and expanding adoptive cell therapy capabilities:

• Immuno-oncology
• ag亚博网站

For over a decade, we have offered an industry-leading array of in vivo imaging modalities for optimum pharmacologic interrogation when needed. These include:

• Flow cytometry
• Imaging
• Radiation

LL / 2：一种免疫抑制鼠肿瘤模型

Lung cancer is the second most common cancer diagnosed in both men and women in the United States and is, by far, the most common cause of cancer-related deaths in men and women. In 2019, the American Cancer Society estimates that 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) will . . .Read more about the LL/2 model

B16-F10: A Murine Melanoma Model

Skin cancers include carcinomas of all layers of the skin with the most common being basal cell (BCC) and squamous cell carcinomas (SCC). Melanoma and non-melanoma skin cancers (Merkel cell carcinoma, Kaposi sarcoma, cutaneous lymphoma and other sarcomas) are much less common. . . .Read more about a murine melanoma model

Preclinical Models of Multiple Myeloma

Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow that is invasive and drug resistant. Patients are generally asymptomatic until very late state disease. There are few preclinical models that recapitulate human disease. In this work, we have evaluated the human MM.1S model and the murine 5TGM1 model . . .Read more about the preclinical models of multiple myeloma

In-Depth Myeloid Cell Characterization in the Murine Syngeneic CT.26 Colon Carcinoma Model by 10-Color Flow Cytometry

The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4 and anti-PD-1, has driven growing interest in methods that provide a mechanistic understanding of drug function. . .Read more about In-Depth Myeloid Cell Characterization

• AACR| 24-29 April | San Diego, CA
• Nonclinical Drug Symposium| 6-7 May, Germany